Set of Tumour-Markers

Abstract

The present invention provides a set of moieties specific for tumor markers, in particular of follicular thyroid carcinoma (FTC) and papillary thyroid carcinoma (PTC) as well as a method for identifying markers of any genetic disease.

1 .- 24 . (canceled) 
     
     
         25 . A set of moieties comprising moieties specific for at least 3 tumor markers, wherein the three tumor markers are further defined as being any three of tumor markers PI-1 to PI-33, PII-1 to PII-64, PIII-1 to PIII-70, FI-1 to FI-147, and PIV-1 to PIV-9. 
     
     
         26 . The set of  claim 25 , wherein the set comprises moieties specific for PIV-4, PIV-5, or any of PV-1 to PV-11. 
     
     
         27 . The set of  claim 26 , wherein at least one of the three tumor markers is further defined as being PV-1, PV-2, or any of PV-4 to PV-11. 
     
     
         28 . The set of  claim 25 , wherein the set comprises moieties specific for at least 3 of the listed tumor markers. 
     
     
         29 . The set of  claim 25 , wherein the set comprises moieties specific for at least 3 tumor markers, wherein the three tumor markers are further defined as being any three of tumor markers PI-1 to PI-33. 
     
     
         30 . The set of  claim 25 , wherein the set comprises moieties specific for at least 3 tumor markers, wherein the three tumor markers are further defined as being any three of tumor markers FI-1 to FI-147. 
     
     
         31 . The set of  claim 25 , wherein the set comprises a moiety specific for the tumor marker SERPINA1. 
     
     
         32 . The set of  claim 25 , further defined as comprising at least 5 moieties specific for the tumor markers of tables 1 to 6. 
     
     
         33 . The set of  claim 32 , further defined as comprising at least 10 moieties specific for the tumor markers of tables 1 to 6. 
     
     
         34 . The set of  claim 25 , wherein the moieties are oligonucleotides specific for tumor marker nucleic acids. 
     
     
         35 . The set of  claim 25 , wherein the moieties are antibodies or antibody fragments. 
     
     
         36 . The set of  claim 35 , wherein the antibodies are further defined as Fab, Fab′ Fab 2 , F(ab′) 2  or scFv, specific for tumor marker proteins. 
     
     
         37 . The set of  claim 25 , wherein the moieties are immobilized on a solid support. 
     
     
         38 . The set of  claim 37 , wherein the solid support is a microarray. 
     
     
         39 . The set of  claim 25 , wherein at least 10% of all analyte binding moieties of the set are moieties which are specific for tumor markers further defined as any combination of PI-1 to PI-33, PII-1 to PII-64, PIII-1 to PIII-70, FI-1 to FI-147, PIV-1 to PIV-9, and PV-1 to PV-11. 
     
     
         40 . The set of  claim 25 , wherein the set comprises less than 50000 analyte binding moieties. 
     
     
         41 . A method for detecting one or more thyroid cancer markers in a sample comprising using the set of  claim 25  and detecting the presence or measuring amount of the occurrence of tumor markers in the sample. 
     
     
         42 . The method of  claim 41 , wherein the sample comprises mammalian cells. 
     
     
         43 . The method of  claim 42 , where the mammalian cells are human cells. 
     
     
         44 . The method of  claim 41 , wherein the detection or measurement is done by RNA-expression analysis, protein analysis, protein microarray detection, mRNA microarray detection, ELISA, a multiplex assay, immunohistochemistry, DNA analysis, comparative genomic hybridization (CGH)-arrays, or single nucleotide polymorphism (SNP)-analysis. 
     
     
         45 . The method of  claim 44 , wherein the detection or measurement is done by tissue microarray detection, microarray analysis, or quantitative PCR. 
     
     
         46 . A method for diagnosis of cancer in a patient comprising:
 providing a sample from the patient;   detecting one or more tumor markers with a set of  claim 25 ;   comparing measured signal values of the tumor markers with values of the tumor markers in a healthy sample; and   diagnosing cancer if more than 50% of the values differ compared to the values of the healthy samples by at least the standard deviation of the method of measurement and/or differ compared to the values of the healthy samples by at least a factor 1.5.   
     
     
         47 . The method of  claim 46 , wherein the sample is a cell sample. 
     
     
         48 . A method for the identification of disease specific markers comprising:
 providing gene expression data on multiple potential disease specific genes of at least two different expression datasets;   determining common genes of the datasets;   normalizing each gene expression dataset;   combining the gene expression datasets to a combined dataset; and   determining genes of the combined data set by determining its nearest shrunken centroid, which includes determination of a cross-validated error value of assigning the genes to the disease and minimizing the error value by reducing the number of members of the combined, preferably normalized, data set;   wherein the genes of the reduced data set are the markers specific for the disease.